Company Overview

Annexon, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies that target the classical complement pathway, a part of the innate immune system implicated in neurodegenerative, autoimmune, and inflammatory diseases. The company’s core scientific approach is centered on inhibiting C1q, the initiating molecule of the classical complement cascade, with the goal of preventing pathological inflammation and tissue damage while preserving other immune functions.

Annexon’s primary business activity is the discovery, development, and potential commercialization of antibody-based therapeutics. Its lead product candidates are designed to address diseases with high unmet medical need, particularly within neurology and rare autoimmune disorders. The company was founded in 2011 and evolved from early academic research into a publicly traded biotechnology firm, completing its initial public offering in 2019 and advancing multiple assets into mid-stage clinical development.

Business Operations

Annexon operates as a single-segment biotechnology company, generating no product revenue to date and funding operations primarily through equity offerings and strategic financing. Its business model is focused on internal research and development, clinical trial execution, and regulatory advancement of its pipeline rather than commercial sales. Core operations include preclinical research, clinical development, regulatory strategy, and intellectual property management.

The company’s lead asset, ANX005, is a monoclonal antibody targeting C1q being evaluated for neurodegenerative and autoimmune indications, including Guillain-Barré syndrome and other neurologic disorders. Additional pipeline programs, such as ANX007, are designed for complement-mediated ophthalmic diseases. Annexon conducts clinical trials globally through third-party contract research organizations and maintains control over its proprietary antibody technologies and complement biology expertise.

Strategic Position & Investments

Annexon’s strategy is focused on establishing leadership in classical complement inhibition as a differentiated therapeutic approach compared to broader complement blockade strategies. The company prioritizes advancing late-stage clinical programs while selectively investing in earlier-stage assets that leverage its core C1q platform. Its pipeline strategy emphasizes diseases with strong biological rationale, measurable biomarkers, and clear regulatory pathways.

The company has historically pursued capital-efficient growth through internal development rather than large-scale acquisitions. Annexon maintains a portfolio of wholly owned product candidates and intellectual property rather than a diversified investment portfolio. Its strategic investments are primarily directed toward clinical trials, manufacturing scale-up, and regulatory readiness for potential future commercialization.

Geographic Footprint

Annexon is headquartered in the United States, with its principal executive offices located in California. The company’s operations are primarily U.S.-based, encompassing research, clinical development oversight, and corporate management.

Internationally, Annexon has a clinical and operational presence across Europe, North America, and other select regions through global clinical trial sites and research partners. While it does not maintain large international offices, its global footprint is defined by multinational clinical studies and regulatory engagement in multiple jurisdictions.

Leadership & Governance

Annexon is led by an experienced executive team with deep backgrounds in biotechnology, neuroscience, and drug development. Leadership emphasizes scientific rigor, disciplined capital allocation, and a focused pipeline strategy aligned with unmet medical needs in complement-mediated diseases.

Key executives include:

• Douglas Love – President and Chief Executive Officer
• Peter Kalias – Chief Financial Officer
• Douglas Anderson – Chief Medical Officer
• Karen Boerneke – Chief Legal Officer and Corporate Secretary
• Christina K. Brennan – Chief Operating Officer

The board and management team collectively guide Annexon’s long-term strategy, governance, and risk oversight, with an emphasis on advancing clinical milestones and creating sustainable shareholder value.